Evidence Grows for Bendamustine-Rituximab Combination for Lymphoma

TOP - February 2013 VOL 6, NO 1 published on March 4, 2013 in Conference Correspondent
Caroline Helwick

Several studies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) found that a regimen that combines bendamustine with rituximab (B-R) may result in superior outcomes compared with the current standard of care, rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) or rituximab plus cyclophosphamide/vincristine/prednisone (R-CVP), in patients with non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL).

A subanalysis of the Study Group on Indolent Lymphomas (StiL) NHL 1-2003 study, which indicated a substantial benefit for B-R in a study presented at ASH in 2011, showed that complete responses (CRs) were more frequent with B-R (39.8%) than with R-CHOP/R-CVP (30.0%). Regardless of the quality of response, first-line treatment with B-R resulted in superior progression-free survival (PFS). In patients with CRs, median PFS exceeded the 5-year evaluation point with B-R, compared with 53.7 months for patients receiving standard therapy.1

In a different noninferiority study—the Bendamustine Rituximab Investigational Non-Hodgkin’s Trial (BRIGHT) of 447 patients—treatment with B-R was associated with CR rate that was noninferior to R-CHOP/R-CVP: 31% versus 25%, meeting the primary objective of the study. The CR rate was significantly higher with B-R in the subgroup of patients with MCL, and quality-of-life scores were higher overall with B-R.2

Investigators for both studies noted that the toxicity profiles of these regimens are very different, which thus can help guide treatment selection.

References
1. Rummel MJ, Niederle N, Maschmeyer G, et al. Subanalysis of the StiL NHL 1-2003 study: achievement of complete response with bendamustine-rituximab (B-R) and CHOP-R in the first-line treatment of indolent and mantle cell lymphomas results in superior survival compared to partial response. Presented at: 54th American Society of Hematology Annual Meeting; December 8-11, 2012; Atlanta, GA. Abstract 2724.
2. Flinn IW, van der Jagt RH, Kahl BS. An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin’s lymphoma (NHL) or mantle cell lymphoma (MCL): the Bright study. Presented at: 54th American Society of Hematology Annual Meeting; December 8-11, 2012; Atlanta, GA. Abstract 902.

Related Items
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Psychological Distress in Patients with Cancer Warrants Attention
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Chemotherapy-Related Side-Effect Concerns Have Evolved, But Hair Loss Remains Significant
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Increased Cancer Risk in Postmenopausal Women with Central Obesity
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Fears of Radiation Side Effects Largely Unfounded
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Netupitant plus Palonosetron Noninferior to Aprepitant plus Granisetron in Patients Receiving Highly Emetogenic Chemotherapy
Li Zhang, MD
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patient-Reported Outcomes Influence Radiation Guidelines
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Healthy Lifestyle Improves Survival in Patients with Colon Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Colorectal Cancer, Conference Correspondent
8-Week Internet-Based Psychological Intervention Reduces Stress in Patients Newly Diagnosed with Cancer
Phoebe Starr
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Hair Loss Seen in 1 of 3 Women with Breast Cancer Receiving Endocrine Therapy
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Last modified: May 21, 2015